Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* diagnosed RA for \>=3 months prior to first administration of study medication;~* inadequate response or intolerance to \>=1 anti-TNF therapies, alone or in combination with methotrexate;~* if using NSAIDS, analgesics or oral corticosteroids, must be on a stable dose for \>=2 weeks prior to start of study.~Exclusion Criteria:~* other chronic inflammatory diseases;~* use of parental corticosteroids within 4 weeks prior to screening;~* severe heart failure, or severe, uncontrolled cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).